ArticleInfection and immunity1999
Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 71 citations in OpenAlex.
- Functional assays to screen and select monoclonal antibodies that targetHuman vaccines & immunotherapeutics · 2023Article
- Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague.Antibodies (Basel, Switzerland) · 2023Article
- Review
- Protection Elicited by Attenuated LiveVaccines · 2021Article
- Review
- Article
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
- A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.Clinical and vaccine immunology : CVI · 2016Article
- Article
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- Expression and Association of the Yersinia pestis Translocon Proteins, YopB and YopD, Are Facilitated by Nanolipoprotein Particles.PloS one · 2016Article
- Protecting against plague: towards a next-generation vaccine.Clinical and experimental immunology · 2013Review
- Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.FEMS microbiology reviews · 2012Review
- Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.Clinical and vaccine immunology : CVI · 2012Article
- The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.Advances in preventive medicine · 2012Article
- Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.Vaccine · 2010Article
- EseD, a putative T3SS translocon component of Edwardsiella tarda, contributes to virulence in fish and is a candidate for vaccine development.Marine biotechnology (New York, N.Y.) · 2010Article
- Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Vaccine · 2010Article
- Biosafety level 2 model of pneumonic plague and protection studies with F1 and Psa.Infection and immunity · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the role of Yersinia outer proteins (Yops) in conferring protective immunity against plague, six yop loci from Yersinia pestis were individually amplified by PCR, cloned, and expressed in Escherichia coli. The recombinant proteins were purified and injected into mice. Most Yop-vaccinated animals succumbed to infection with either wild-type encapsulated Y. pestis or a virulent, nonencapsulated isogenic variant. Vaccination with YpkA significantly prolonged mean survival time but did not increase overall survival of mice infected with the nonencapsulated strain. The only significant protection against death was observed in YopD-vaccinated mice challenged with the nonencapsulated strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.